Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05396885 · ClinicalTrials.gov registry record · Phase 2

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

A Phase 2 study of Multiple Myeloma, sponsored by Kite, A Gilead Company.

Active
Registry status
Phase 2
Development phase
136
Enrollment target
18
Study locations

NCT05396885: Active Phase 2 study of Multiple Myeloma, sponsored by Kite, A Gilead Company.

NCT05396885 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Kite, A Gilead Company. The registered enrollment target is 136 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05396885, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Kite, A Gilead Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
136 participants
Enrollment target
18
Study locations

Study Summary

A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.

Conditions Studied

Multiple Myeloma

Interventions

  • BIOLOGICAL anitocabtagene-autoleucel

Study Locations (18)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Wisconsin

  • University of Wisconsin Clinical Science Center - Madison
  • Froedtert Hospital & the Medical College of Wisconsin - Milwaukee

Arizona

  • HonorHealth Cancer Transplant Institute - Scottsdale

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Colorado

  • Colorado Blood Cancer Institute - Denver

Florida

  • Moffitt Cancer Center - Tampa

Georgia

  • Northside Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2022-07-15
Est. Completion 2026-12
Phase Phase 2

Sponsor

Kite, A Gilead Company

28 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05396885

The ClinicalTrials.gov registry entry for NCT05396885 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower). The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which anitocabtagene-autoleucel is the first listed.

NCT05396885 reports 18 study locations spanning 15 distinct geographic areas - top geographies include Massachusetts, Texas, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT05396885 about?

NCT05396885 is a clinical study titled "Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)". A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.

What is the current status of trial NCT05396885?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2022-07-15. Estimated completion is 2026-12.

What conditions does trial NCT05396885 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05396885?

The interventions under investigation include: anitocabtagene-autoleucel (BIOLOGICAL).

Who is sponsoring clinical trial NCT05396885?

This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05396885 being conducted?

This trial has 18 study locations across Arizona, Arkansas, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.